Neurotech & BCI
The best-positioned European BCI pure-play and the only graphene-native one — but it is a Series-B, pre-revenue spin-off two full funding rounds behind Neuralink/Precision, and its material moat is unproven precisely where its closest competitor (Precision's Layer 7) already has FDA clearance; a watch-and-wait private, not yet investable, gated on a Series C + a graphene-specific regulatory de-risking event.
Research
The verdict
The best-positioned European BCI pure-play and the only graphene-native one — but it is a Series-B, pre-revenue spin-off two full funding rounds behind Neuralink/Precision, and its material moat is unproven precisely where its closest competitor (Precision's Layer 7) already has FDA clearance; a watch-and-wait private, not yet investable, gated on a Series C + a graphene-specific regulatory de-risking event.
INBRAIN Neuroelectronics is a Barcelona-based brain-computer-interface therapeutics (BCI-Tx) company — the distinction is the whole thesis. Founded in 2019 as a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2), ICREA, IMB-CNM-CSIC and the EU Graphene Flagship programme. Where Neuralink and Synchron chase assistive BCI (let a paralysed person move a cursor), INBRAIN is building a closed-loop neuromodulation device that reads and writes neural signals to treat disease — Parkinson's first, then epilepsy, stroke rehabilitation and, prospectively, psychiatric/memory disorders.
The differentiator is the material: an ultrathin (~10 µm, thinner than a human hair) graphene cortical/cortical-surface interface, versus the platinum/iridium and silicon microelectrodes everyone else uses. The pitch is that graphene's conductivity, surface area, flexibility and biocompatibility let it record function-specific biomarkers "metals can barely see," conform to the brain surface with less tissue damage, and — critically — both sense and stimulate at micrometric resolution (a bidirectional interface), enabling adaptive personalised stimulation rather than the fixed open-loop pulse of a 2010s DBS device.
Structure. Two vehicles:
Customers / payment structure. Pre-revenue — there is no commercial product and no recurring revenue. Future model is a high-acuity implantable medical device sold into neurosurgery / movement-disorder centres, reimbursed through DBS-style procedure + device-and-programming pathways. The current "customers" are really partners and grant bodies: Merck KGaA (pharma co-development), Microsoft (Azure AI), imec (manufacturing scale-up), the EU/Spanish state (EIC, CDTI, PERTE Chip), and the NHS/University of Manchester clinical sites. `` customers.csv is empty — confirmed no disclosed revenue concentration because there is no revenue.
Mapped upstream → INBRAIN → end patient, named stakeholders:
Chokepoint / single-source risk. The defining dependency is neural-grade graphene fabrication at GMP scale. This is INBRAIN's moat and its single largest execution risk: there is no merchant market for implantable graphene electrodes, so the company must essentially industrialise a new materials supply chain itself (with imec / Spanish fabs). The chain "fails generic" warning from the skill is satisfied with named parties — but note that headcount, GMP-line status and yield are not disclosed ``, and that opacity is itself a flag for a hardware company claiming a near-term scale story.
The moat is the material + the IP around it. INBRAIN is a top innovator in a field of 2,160+ BCI patent families across 664 organisations, specifically as the recognised leader in graphene-based neural interfaces. The patent estate traces to ICN2/IMB-CNM/ICREA and the Graphene Flagship and is genuinely differentiated — almost nobody else is building a clinical-stage graphene cortical interface. Durable-moat assessment:
Verdict on moat: narrow-but-real materials/IP edge + a smart therapeutics positioning, undercut by the fact that the closest "thin, flexible, high-channel-count" competitor (Precision Neuroscience) reached FDA clearance first with a non-graphene film (Lens 7/12).
`` segments.csv is empty — no segment revenue exists (pre-revenue). Structural segmentation by program / vehicle rather than revenue:
| Segment | Vehicle | Target | Stage | Status |
|---|---|---|---|---|
| Cortical BCI-Tx (decode + modulate) | INBRAIN S.L. | Parkinson's (lead), epilepsy, stroke | First-in-human (mapping/decoding) complete; therapeutic DBS-replacement pre-clinical→IND-track | FDA Breakthrough Device Designation (Parkinson's) |
| Intraoperative brain mapping / tumour resection | INBRAIN S.L. | Neurosurgery (awake language/function mapping) | First-in-human trial enrolment complete Apr 2026 (10 enrolled, 8 surgically treated) | Earliest realistic first commercial wedge |
| Peripheral / vagus-nerve bioelectronics | Innervia Bioelectronics | Inflammatory, metabolic, endocrine disease | Pre-clinical co-development | Merck KGaA partnership |
| AI platform layer | INBRAIN + Microsoft | Closed-loop adaptive modulation | Collaboration announced Nov 2025 | Azure agentic-AI |
The intraoperative mapping segment is the under-appreciated one: it is a far shorter regulatory path (an acute, sub-30-day surgical-tool use, like Precision's cleared indication) than a chronic implanted Parkinson's therapy, and is the most plausible route to first revenue — though the company frames itself around the bigger Parkinson's prize.
+private +clinical swap: funding trajectory + pipeline-by-phase)INBRAIN has raised ~$99.85M across ~12 rounds to date, per aggregators. Round history:
| Date | Round | Amount | Lead / notable | Note |
|---|---|---|---|---|
| ~2020 | Seed / early | part of €14–15M early tranche | Asabys Partners, Aliath Bioventures, Vsquared | ICN2/Graphene-Flagship spin-off raise |
| 2021 | Strategic | undisclosed | Merck KGaA (+ collaboration) | Innervia vagus-nerve co-dev |
| Oct 2024 | Series B | $50M | imec.xpand (lead); EIC Fund, Fond ICO Next Tech, CDTI-Innvierte, Avançsa; existing Asabys/Aliath/Vsquared | Brought total since inception to $68M; Merck added separate funding |
| May 2025 | Grant (PERTE Chip / "Grant-II") | €4M / ~$4.53M | Spain PERTE Chip programme | Graphene BCI fabrication |
No earnings calls exist. Tone read from CEO Carolina Aguilar's public interviews/talks (Inside Precision Medicine, LSI, imec ITF, elemed): consistently therapeutics-first, disease-modification framing — "the larger opportunity is to treat disease directly, not just decode the brain." Messaging is disciplined and commercially literate (she ran a real P&L), not the moonshot-hype register of some BCI peers. Recurring themes: graphene as enabling material, closed-loop adaptive therapy, Parkinson's as the wedge, European deep-tech sovereignty. No tonal red flags (no over-promising on timelines to approval; she is careful to say BDD ≠ approval).
Cap table / secondary: Syndicate is strategic-European (imec.xpand, EIC Fund, CDTI, Asabys, Aliath, Vsquared, Merck KGaA strategic). ~20 investors per aggregators. No crossover-fund / late-stage-growth marks public; secondary marks n/a — not disclosed.
BCI peer comps (the real benchmark — by funding/stage/approach, since multiples don't exist for any of these private names):
| Company | Total funding | Latest valuation | Approach | Channels | Regulatory status |
|---|---|---|---|---|---|
| INBRAIN | ~$100M | n/a — not disclosed | Graphene cortical, bidirectional, therapeutic | µm-scale contacts | FDA Breakthrough Device Desig. (Parkinson's); FIH mapping trial enrolment complete Apr 2026 |
| Neuralink | ~$1.85B | ~$9.6B (≈$7.8–9.6B) | Penetrating threads, implanted robot | 1,024 electrodes (N1) | IDE feasibility; >dozen participants mid-2026 |
| Synchron | ~$345M+ ($200M Series D, Nov 2025) | ~$385M (Series C era) | Endovascular stentrode (no craniotomy) | 16 electrodes | Pivotal FDA PMA trial planned 2026 |
| Precision Neuroscience | ~$155M ($102M Series C, Dec 2024) | n/a — not disclosed | Thin-film surface array (Layer 7) | 1,024 (up to 4,096 recorded) | FDA 510(k) CLEARED, Mar 2025 |
| Paradromics | ~$123M (+$18M NIH/DARPA) | n/a — not disclosed | Penetrating high-bandwidth (Connexus) | >200 bits/s ITR | First human implant mid-2025 |
Mechanism takeaway: INBRAIN is the only graphene-native player and the most explicitly therapeutic/DBS-replacement positioned — a genuinely differentiated lane. But on capital and regulatory progress it is behind: ~$100M raised vs. Neuralink's ~$1.85B, and Precision Neuroscience already holds FDA 510(k) clearance for a competing thin, flexible, high-channel surface array — the exact "minimally invasive, conformal, high-resolution" claim INBRAIN makes for graphene, achieved first with a non-graphene film. That is the central comp risk.
For a private, the equivalent of "what moves the stock" is what moves the narrative and the next mark:
Pattern: the market (private investors) reacts to clinical firsts and major-partner validation. The next narrative-moving events are a Series C and full data readout / publication from the completed FIH study.
CEO & co-founder — Carolina Aguilar. The standout asset of the whole company. ~20 years in healthcare; 13 years at Medtronic (European HQ, Switzerland), a decade running the global neuromodulation / Deep Brain Stimulation business with a P&L of >$140M, plus value-based-healthcare deal-making (won the 2017 European VBHC prize, signed a Saudi diabetes VBHC deal). This is precisely the rare profile a therapeutic-BCI company needs: someone who has actually sold and reimbursed DBS at scale, not just an academic or a software founder. Background started in toxicology / Parkinson's–pesticide research — domain-aligned. Skin in the game: co-founder equity (material) ``; exact stake not disclosed.
Scientific founders: Prof. Jose A. Garrido (ICREA, ICN2 Advanced Electronic Materials group — CSO; also inside the INNOFAB fab initiative), Prof. Kostas Kostarelos (Professor of Nanomedicine, University of Manchester — Chief Scientific Investigator on the FIH study), and Dr. Anton Guimerà (IMB-CNM-CSIC). This is a first-rate scientific bench — the people who literally pioneered graphene neural interfaces, embedded in the EU Graphene Flagship.
Archetype: a professional-operator CEO (ex-Medtronic) on top of an elite academic founding team — arguably the ideal configuration for a clinical-stage neuromodulation company (commercial discipline + deep science), and a notable contrast to founder-engineer-led peers. Capital-allocation history is short (one priced round) but disciplined (grant-funded fab build, partner-funded programmes conserve dilution). Red flags: none material on the people; the risk is execution/capital, not governance.
There is no audited financial statement to forensically dissect — INBRAIN is a private Spanish S.L. with no SEC filings (research-layer: filings=0, CIK=null). So this lens is necessarily about disclosure quality and structural risk, not income-statement forensics:
Regulatory findings (required sub-section). Per regulatory/regulatory-findings.md (fetched 2026-06-24): INBRAIN has no SEC CIK — it is private and files nothing with the SEC, so no EDGAR Litigation Releases or AAERs are searchable; 0 SEC findings. Non-SEC web search ("Inbrain Neuroelectronics" (FTC OR DOJ OR FDA OR settlement OR fine OR penalty) enforcement) returns no material enforcement, litigation, consent decree, or penalty against INBRAIN. On the FDA side the only material interactions are positive (Breakthrough Device Designation for the Parkinson's platform; the FIH study runs under University-of-Manchester sponsorship / UK MHRA-style oversight, no safety holds reported). Conclusion: no material regulatory or legal findings — verified via SEC EDGAR EFTS (no CIK → none possible), web enforcement search, and public clinical disclosures as of 2026-06-24. All findings web-sourced and unaudited per the private-company limitation.
+clinical swap: rNPV / runway-to-catalyst, not EPS)There is no EPS to project (pre-revenue, private). Two projections that matter:
(a) Path-to-tradeable / IPO readiness. On the skill's 1–5 scale: INBRAIN ≈ 2 (growth-stage), not pre-IPO.
private-watch.json entry for INBRAIN today — this name should be added to the be-early ledger (beat: bci, stage: growth/Series-B, ipo_readiness: 2, lead: imec.xpand, catalyst: "Series C + FIH data readout + GMP graphene scale; likely strategic-M&A exit"). (Noted for Connor to action; this unattended run does not edit research/ files per the wave boundaries.)(b) Runway-to-catalyst (the question that actually matters for a clinical private). Does cash reach the next value-inflection event? ``: $50M Series B (Oct 2024) + €4M grant (May 2025), against dual-programme clinical + graphene-fab burn → runway plausibly into 2026–2027. The next value-inflection catalysts are: the full FIH study readout/publication (enrolment completed Apr 2026 → data H2 2026), and the Series C raise. The bear scenario is a runway-to-catalyst gap — needing to raise before a clean therapeutic dataset, into a tougher 2026 venture market for capital-intensive hardware, at a flat or down mark.
Brier forecast (per skill, clinical names log a binary readout, not an EPS line): Candidate — "INBRAIN announces a closed Series C (or strategic equity round >$40M) by 2026-12-31, p≈0.45 ``." Not logged — forecast.ts create is skipped in the unattended --watchlist loop per the skill (only log a forecast on a genuinely committed base case); recorded here for Connor to action if he promotes this name.
Bull case. INBRAIN is the only graphene-native BCI company, with a first-rate scientific founding team, a world-first human graphene implant already done, FDA Breakthrough Device Designation for Parkinson's, and — uniquely among BCI startups — a CEO who ran a >$140M DBS P&L at Medtronic. It is aimed at the right market (disease-modifying neuromodulation / DBS replacement — large, reimbursed, real) rather than the speculative assistive-cursor space. If graphene's bidirectional, micrometric, low-immune-response profile delivers a clinically meaningful advantage over platinum/PtIr and thin-film for adaptive Parkinson's therapy, INBRAIN owns a defensible materials franchise and is an obvious strategic acquisition target for Medtronic/Boston Scientific/Abbott. The Merck and Microsoft deals validate both the therapeutic and the AI-platform optionality. It is the best-positioned European BCI pure-play.
Bear case (2–3 permanent-impairment risks).
Pre-mortem (18 months out, thesis broke): INBRAIN had to raise a Series C in late 2026 before a clean therapeutic dataset, took a flat/down round in a cold hardware market, while Precision Neuroscience (already FDA-cleared) and Synchron (in pivotal PMA) pulled commercially ahead — and the graphene clinical advantage proved real but not differentiating enough to command a premium, so the most likely outcome compressed to a modest strategic acquisition.
Contrarian view of what the market refuses to see: the crowd narrative is "BCI = Neuralink = paralysis/cursor moonshot." INBRAIN is a different and arguably better business — a reimbursed-market neuromodulation play run by a DBS commercial veteran. The market under-weights the ex-Medtronic-operator + DBS-replacement angle and over-indexes on channel counts and Musk headlines.
Dismantling the bull case:
The safest, most surgically scalable path into the brain and the only BCI Apple made a native input — but it bet the company on "good enough" 16-electrode bandwidth, and its own third-gen "whole-brain" pivot is a confession that the moat it is famous for may be the ceiling it has to escape.
A first-mover NGPS tools story whose commercial engine is going backwards (revenue −20% in FY25, −69% in Q1'26 to $258K) while it bets the company on Proteus by end-2026; ~$190M cash funds the bet, but a 69%-Rothberg-controlled sub-$1 microcap with collapsing instrument demand is a binary option, not an investment — WATCHING until Proteus ships and consumable pull-through proves real.
The only FDA-cleared, commercially-shipping cortical BCI — but it is selling a 30-day surgical-monitoring tool, not the chronic implant the $500M valuation is priced on; Medtronic is the real tell, IP overhang from Rapoport's Neuralink past is the real risk.